/PLSE
PLSE Stock - Pulse Biosciences, Inc.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$15.26+6.12%
+$0.88 (+6.12%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.48
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $16.79
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PLSE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.11 – $15.41
TARGET (TP)$17.55
STOP LOSS$14.04
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.80
52W High$25.00
52W Low$12.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $700,000 | $1.42M | N/A |
| Gross Profit | N/A | $-1,207,000 | $-11,244,000 | $-550,000 | $-1,095,000 |
| Gross Margin | N/A | N/A | -1606.3% | -38.8% | N/A |
| Operating Income | $-56,257,000 | $-43,574,000 | $-58,057,000 | $-63,014,000 | $-49,965,000 |
| Net Income | $-53,585,000 | $-42,210,000 | $-58,505,000 | $-63,660,000 | $-49,737,000 |
| Net Margin | N/A | N/A | -8357.9% | -4489.4% | N/A |
| EPS | $-0.92 | $-0.88 | $-1.72 | $-2.28 | $-2.14 |
Company Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$22
Average Target
↑ 44.2% Upside
Now
$22
Low
$22
Average
$22
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 7th 2025 | Oppenheimer | Initiation | Outperform | $22 |
Earnings History & Surprises
PLSEBeat Rate
78%
Last 18 quarters
Avg Surprise
+17.6%
EPS vs Estimate
Beats / Misses
14/3
1 met exactly
Latest EPS
$-0.29
Q4 2025
EPS Surprise History
Q1 24
+37.5%
$-0.15vs$-0.24
Q2 24
+41.7%
$-0.14vs$-0.24
Q3 24
+17.1%
$-0.20vs$-0.24
Q4 24
+33.3%
$-0.16vs$-0.24
Q1 25
+29.2%
$-0.17vs$-0.24
Q2 25
No data
Q3 25
-7.7%
$-0.28vs$-0.26
Q4 25
+6.5%
$-0.29vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.32 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.31 | $-0.29 | +6.5% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.26 | $-0.28 | -7.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | — | $-0.17 | — | — |
Q1 2025 | Mar 27, 2025 | $-0.24 | $-0.17 | +29.2% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.24 | $-0.16 | +33.3% | ✓ BEAT |
Q3 2024 | Aug 19, 2024 | $-0.24 | $-0.20 | +17.1% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.24 | $-0.14 | +41.7% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.22 | $-0.23 | -4.5% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.24 | $-0.22 | +8.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.45 | $-0.46 | -2.2% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.37 | $-0.37 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.51 | $-0.48 | +5.9% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.50 | $-0.39 | +22.0% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.54 | $-0.42 | +22.2% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.79 | $-0.48 | +39.2% | ✓ BEAT |
Q2 2021 | May 10, 2021 | $-0.52 | $-0.43 | +17.3% | ✓ BEAT |
Latest News
Pulse Biosciences Announces FDA IDE Approval To Begin nPulse Cardiac Catheter Ablation Study In Paroxysmal Atrial Fibrillation
📈 PositiveBenzinga•Dec 18, 2025, 12:08 PM
Pulse Biosciences Teams Up With MD Anderson To Test New Thyroid Cancer Treatment In FDA-Approved Study
📈 PositiveBenzinga•Dec 9, 2025, 12:10 PM
Pulse Biosciences Q3 EPS $(0.29) Beats $(0.31) Estimate, Sales $86.000K Miss $500.000K Estimate
➖ NeutralBenzinga•Nov 5, 2025, 09:26 PM
Pulse Biosciences Announces Enrollment Of First Patient In NANOCLAMP AF Study For Treatment Of Atrial Fibrillation
📈 PositiveBenzinga•Oct 24, 2025, 11:01 AM
Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting
📈 PositiveBenzinga•Oct 10, 2025, 11:02 AM
Pulse Biosciences To Present Early Clinical Data On nPulse Cardiac Surgical System At 39th European Association For Cardio-Thoracic Surgery Meeting
➖ NeutralBenzinga•Oct 7, 2025, 11:14 AM
Pulse Biosciences (NASDAQ: PLSE) To Showcase nPulse Vybrance Clinical Data On Benign Thyroid Nodule Ablation At American Thyroid Association 2025 Annual Meeting
📈 PositiveBenzinga•Sep 10, 2025, 11:19 AM
PLSE stock has given up its prior gain. Pulse Biosciences shares were trading higher after the company announced that the FDA granted approval for its Investigational Device Exemption, allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation.
📈 PositiveBenzinga•Sep 8, 2025, 04:56 PM
Pulse Biosciences shares are trading higher after the company announced that the FDA granted approval for its Investigational Device Exemption, allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation.
📈 PositiveBenzinga•Sep 8, 2025, 12:41 PM
Pulse Biosciences Announces FDA Granted Approval For Investigational Device Exemption, Allowing It To Proceed With Initiation OfnsPFA Cardiac Surgery System Study
📈 PositiveBenzinga•Sep 8, 2025, 11:01 AM
Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules
📈 PositiveBenzinga•Sep 2, 2025, 11:05 AM
Pulse Biosciences Announced A New Publication In The Journal Thyroid, The First-in-human Clinical Feasibility Study Demonstrates The Effectiveness Of Ablation Of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation (nsPFA) Energy
📈 PositiveBenzinga•Aug 26, 2025, 11:05 AM
Frequently Asked Questions about PLSE
What is PLSE's current stock price?
Pulse Biosciences, Inc. (PLSE) is currently trading at $15.26 per share. The stock has moved +6.12% today.
What is the analyst price target for PLSE?
No analyst price targets are currently available for this stock.
What sector is Pulse Biosciences, Inc. in?
Pulse Biosciences, Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is PLSE's market cap?
Pulse Biosciences, Inc. has a market capitalization of $1.03 billion, making it a small-cap company.
Does PLSE pay dividends?
No, Pulse Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
BBNX
Beta Bionics, Inc.
$29.25
Mkt Cap: $1.3B
DNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$27.32
Mkt Cap: $1.6B
LFMD
LifeMD, Inc.
$3.23
Mkt Cap: $0.2B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
NVCR
NovoCure Limited
$12.84
Mkt Cap: $1.4B
OPK
OPKO Health, Inc.
$1.31
Mkt Cap: $1.0B
STAA
STAAR Surgical Company
$25.14
Mkt Cap: $1.2B
Explore stocks similar to PLSE for comparison